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Background: Liver injury due to prescription and nonprescription medications is an expanding public health
concern in the United States, with drug-induced liver injury (DILI) being the single most common reason for
regulatory actions instituted by the Food and Drug Administration against certain medications and supplements.
Case presentation: A 69-year-old Latino man was referred to Hepatology Clinic for urgent evaluation of new onset
jaundice, nausea and fatigue associated with a >40-fold increase in his transaminase levels and elevated INR and
alkaline phosphatase. The patient had received a new prescription for varenicline to aid with smoking cessation
approximately 3 weeks prior to his evaluation in Hepatology Clinic. Within 5 days of starting the varenicline, the
patient developed new onset of nausea, vomiting, malaise and deep jaundice. The varenicline was discontinued on
day 5 by the patient. Hepatologic evaluation revealed no evidence of acute viral hepatitis, autoimmune, metabolic
or alcohol-related liver disorders. The patient’s past medical history was notable, however, for chronic hepatitis C.
His liver enzymes and synthetic function completely normalized 9 weeks after discontinuation of the varenicline.
Conclusion: This report represents the second documented cases of drug-induced liver injury related to varenicline
therapy, highlighting the need for clinician awareness regarding potential hepatotoxicity of varenicline, particularly
among patients with pre-existing liver disease.
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Drug-induced liver injury (DILI) is an adverse drug reac-
tion that results in acute liver injury ranging in severity
from mild, asymptomatic elevations in liver biochemis-
tries to acute liver failure culminating in death or liver
transplantation. Liver injury due to prescription and
nonprescription medications is an expanding public
health concern in the United States, with DILI being the
single most common reason for regulatory actions insti-
tuted by the Food and Drug Administration against cer-
tain medications and supplements [1]. The incidence of
DILI has been challenging to quantify due to it being a
relatively uncommon clinical entity, and also due to
under-recognition of the disorder; however, the world-
wide annual incidence rate of DILI is estimated to be ap-
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distribution, and reproduction in any mediumwith DILI accounting for 3-9 % of all adverse drug reac-
tions reported to health authorities [2-4]. DILI, whether
acetaminophen-induced or idiosyncratic, has been impli-
cated in up to 50 % of acute liver failure cases in the
United States. Depending on the inciting pharmacologic
agent, DILI has been associated with a case-fatality rate
of 10-50 %. Thus, given the continually expanding
market of prescription and nonprescription medications
and supplements, DILI will remain a clinically important
etiology of acute liver injury, making timely and accurate
reporting of DILI important for the early detection and
awareness of drug-induced hepatotoxicity.
We present a case of hepatotoxicity associated with
varenicline use. Varenicline is a partial agonist at the
α4β2 nicotinic acetylcholine receptors and is supplied as
an orally administered tablet. It may be used alone or in
combination with other smoking cessation agents as a
first-line therapy for smoking cessation. Commonly
reported side effects to varenicline include nausea,
vomiting, neuropsychiatric and sleep disturbances. Tod Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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varenicline-associated hepatotoxicity [5].
Case presentation
A 69-year-old Latino man was seen for urgent consul-
tation in the outpatient Hepatology Clinic for evaluation
of new onset jaundice and substantially elevated liver
enzymes associated with nausea and extreme malaise
that developed three weeks prior to presentation. The
patient’s past medical history was notable for type 2
diabetes mellitus, hypertension and tobacco abuse. He
had no known diagnosis of chronic liver disease prior to
the onset this illness. The patient was a widower and
retired foreman of a starch plant who endorsed a greater
than 25 pack-year smoking history and an alcohol his-
tory of 1–2 cans of beer per week, on average. His last
drink was one month prior to the onset of the current
illness. He had a history of tattooing as a teenager, but
denied history of recreational drug use and denied any
non-prescription or herbal supplement use. His family
history was significant for both diabetes and coronary ar-
tery disease; there was no known family history of liver
disease.
The patient was in his usual state of health and feeling
quite well when he presented to his primary care pro-
vider for a routine health maintenance check-up ap-
proximately 3 weeks prior to presentation in Hepatology
Clinic. At that time, the patient was counseled regarding
the health benefits of smoking cessation, particularly
given his known history of diabetes and hypertension.
The patient was receptive to smoking cessation interven-
tion and was prescribed varenicline 0.5 mg orally once
daily, which he began taking four weeks prior to his
presentation in Hepatology Clinic. The patient also con-
tinued on his long-term chronic medications that
included: metformin 850 mg orally twice daily, aspirin
81 mg orally daily, valsartan 80 mg orally daily, and sil-
denafil 50 mg orally daily as needed. Five days after
starting the varenicline, the patient developed new onset
nausea, vomiting, decreased appetite, weight loss and ex-
treme malaise. The patient’s son noticed yellowing of his
father’s eyes and prompted him to seek immediate med-
ical attention. Given these symptoms, the patient discon-
tinued the varenicline on his own at day 5. The patient
was seen by his primary care provider approximately
two-and-a-half weeks after starting the varenicline. Liver
chemistries performed at that time revealed the follow-
ing: aspartate aminotransferase (AST) = 1191 U/L, ala-
nine aminotransferase (ALT) = 1592 U/L, alkaline
phosphatase (Alk Phos) = 254 U/L, total bilirubin
(TBili) = 12.0 mg/dL, INR= 1.3, platelets = 289 x 106
cells/mL and serum creatinine = 1.0 mg/dL. His INR was
mildly elevated at 1.3 and serum albumin was normal at
4.0 g/dL. Hemoglobin and white blood cell counts werewithin normal limits. No peripheral eosinophilia was
noted. Acetaminophen and alcohol levels were undetec-
table. Viral hepatitis serologies were negative for hepa-
titis A (HAV) IgM, hepatitis B (HBV) sAg, and HBc
IgM. Hepatitis C (HCV) Ab was noted to be positive. As
the patient had no known antecedent history of abnor-
mal liver enzymes, he had never previously been tested
for HCV. A CT scan of the abdomen revealed a normal
appearing liver without any evidence for cirrhosis or bil-
iary ductal dilation or hepatic masses. Hepatic artery,
hepatic veins and portal veins were all patent. Magnetic
resonance cholangiopancreatography (MRCP) was also
performed and was negative.
Due to the significant hepatitis and hyperbilirubinemia,
the patient was seen urgently in our Outpatient Hepatol-
ogy Clinic, marking approximately three weeks after the
onset of symptoms. At the time of the visit, the patient
continued to complain of significant nausea, vomiting,
poor appetite, 10-pound weight loss, dark urine and per-
sistent jaundice. He continued to abstain from the use of
varenicline. On physical examination, the patient was
5’6” tall and weighed 125 pounds. He had prominent bi-
lateral scleral icterus and jaundiced skin. No skin rashes
or lymphadenopathy were noted. Abdominal exam was
unremarkable, without distention, tenderness or hepatos-
plenomegaly. There were no classical stigmata of chronic
liver disease. Repeat laboratory studies were performed
at the time of the Hepatology consultation and revealed
the following: AST= 334 U/L, ALT= 515 U/L, T Bili =
18.1 mg/dL, INR= 1.2, Albumin = 3.3 g/dL and Alk
Phos = 137 U/L. HCV genotype was 1a with HCV RNA
level of 55,100 IU/mL. HIV testing was negative. Further
laboratory testing demonstrated that the patient was
negative for HBV DNA, anti-nuclear antibody, anti-
smooth muscle antibody and anti-mitochrondrial anti-
body. Immunoglobulin and thyroid stimulating hormone
levels were normal and alpha-1-antitrypsin phenotype
was MM. Testing for hemochromatosis and celiac sprue
were negative. Evaluation for other acute viral infections,
including herpes simplex (HSV)-1 and −2, Epstein Barr
virus (EBV) and Cytomegalovirus (CMV) were negative.
Approximately two months after stopping the vareni-
cline, the patient’s AST, ALT and Alk Phos had normal-
ized with near-normalization of the T Bili. (Figures 1
and 2) He reported a substantial improvement in his
health status and normalization of his activity levels with
resolution of the nausea, vomiting, fatigue and jaundice,
and a return of his appetite. A percutaneous liver biopsy
was performed at this point with the goal of grading and
staging the patient’s HCV and demonstrated changes
consistent with chronic HCV, grade 2, stage 2 disease.
Also noted, however, were focal lobular aggregates of

















Figure 1 Evolution of aspartate (AST) and alanine (ALT)
aminotransferase levels with varenicline exposure and
discontinuation.
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patient’s clinical history. The patient was instructed
never to rechallenge himself with varenicline and to
report it as a medication adverse reaction in the future.
Conclusion
Acute hepatic injury caused by drugs, both prescription
and non-prescription, is termed drug-induced liver in-
jury (DILI). DILI may range in severity from mild,
asymptomatic, elevations in liver enzymes to severe hep-
atic injury culminating in acute liver failure resulting in
either death or liver transplantation. There are currently























Figure 2 Evolution of total bilirubin (T Bili) levels with
varenicline exposure and discontinuation.causing DILI. DILI may be predictable and dose-
dependent, as classically exemplified by acetaminophen
toxicity, or may be idiosyncratic [6-8]. Idiosyncratic
drug-induced liver injury, as exemplified in the current
case report of varenicline, represents a complex inter-
action between an individual’s unique metabolic and
genetic characteristics and the drug [9,10]. Idiosyncratic
drug-induced liver injury is unpredictable and not dir-
ectly related to the dose, duration or route of adminis-
tration of the drug. The majority of suspect drugs
involved in cases of idiosyncratic DILI were not asso-
ciated with hepatotoxicity in the preclinical or early cli-
nical testing of the drug. This is likely the result of
several factors including: the relative rarity of severe
idiosyncratic DILI, which has a reported incidence
between 1 in 10,000 and 1 in 100,000 patients exposed;
and the relatively small size of most clinical drug trials
with respect to detecting such an uncommon event as
severe DILI. This scenario is best exemplified by troglita-
zone (RezulinW), which was ultimately withdrawn from
the market in 2000 due to multiple reported cases of
acute liver failure [11]. Therefore, it may not be until a
drug comes to market and thousands of patients are
exposed to the drug that cases of DILI begin to be
recognized. This phenomenon also underscores the im-
portance of clinical providers reporting cases of sus-
pected DILI to the Food and Drug Administration.
The diagnosis of DILI can be challenging as there are
no specific diagnostic tests and DILI is essentially a diag-
nosis of exclusion of other etiologies of acute liver injury.
The diagnosis may be even more challenging in the set-
ting of known chronic liver disease and in patients tak-
ing multiple potentially hepatotoxic drugs. The
evaluation of the patient with suspected DILI should in-
clude laboratory testing and clinical assessment for an
array of etiologies of abnormal liver function, including:
viral hepatitis, excessive alcohol use, autoimmune liver
disease, vascular disorders of the liver and metabolic
liver diseases. Evidence for hepatic ischemia and biliary
disease should also be pursued.
In the case report presented here, DILI due to vareni-
cline was the most likely etiology of our patient’s acute
liver injury. Extensive testing for other causes of acute
liver injury was negative and the patient did not endorse
signs, symptoms or imaging findings suggestive of out-
flow obstruction, hepatic ischemia or biliary obstruction.
Although the patient was discovered to be HCV Ab
positive with detectable HCV RNA, this was very un-
likely to be an acute infection given his lack of recent
risk factors for HCV acquisition and his liver biopsy
demonstrating stage 2 fibrosis.
DILI may be classified into three categories based
upon the pattern of liver injury observed: (1) acute
hepatocellular injury; (2) cholestatic injury; and (3)
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substantial damage to the hepatocytes and is character-
ized by elevations in the serum AST and ALT levels,
with lesser elevations in the Alk Phos level. Cholestatic
injury results from either direct injury to the biliary
epithelium or injury to the molecular processes
involved in bilirubin metabolism and secretion and is
characterized by disproportionately elevated Alk Phos
and T Bili levels. Mixed liver injury has both hepato-
cellular and cholestatic features. Notably, T Bili may
be substantially elevated in any of these three categor-
ies of liver injury and generally signifies more severe
liver injury. In the case of our patient, he demon-
strated a predominantly hepatocellular injury that oc-
curred with a substantially elevated T Bili and a mild
elevation in his INR, consistent with a moderately se-
vere liver injury.
Assessing causality in suspected cases of DILI remains a
challenge. Two algorithms specifically designed for DILI
causality assessment, the Roussel Uclaf Causality Assess-
ment Model [RUCAM] and the Maria & Victorino [M&V]
Scale, have been published and, although they are not
widely used in the clinical setting, they do offer useful fra-
meworks for thinking about the patient with suspected
DILI [13,14]. The RUCAM assesses several different
domains, including: chronological relationship between the
drug exposure and hepatic injury, risk factors, concomitant
drug use, evaluation for other etiologies of liver injury, pre-
existing data regarding the hepatotoxic potential of the sus-
pected drug, and response of the patient to clinical rechal-
lenge with the suspected drug. Using the RUCAM, a score
ranging from −9 to 14 is generated and patients are
grouped into categories of: DILI excluded; DILI unlikely;
DILI possible; DILI probable; and DILI highly probable. Ap-
plying the RUCAM causality assessment tool to our case
results in varenicline being rated as the “probable” cause of
DILI. The M&V scale was developed in an attempt to sim-
plify the scoring system for DILI. The M&V scale focuses
on: the time course of the drug exposure and its relation-
ship to the liver injury, exclusion of completing causes of
liver injury, pre-existing data implicating the suspected drug
in causing liver injury, and response of the patient to rechal-
lenge with the suspected drug. Using the M&V scoring sys-
tem, a score ranging from −8 to 20 is generated and
patients are grouped into five categories rating the likeli-
hood of DILI: DILI excluded; DILI unlikely; DILI possible;
DILI probable; DILI definite. In applying the M&V scale to
our case, varenicline is categorized as a “possible” cause of
DILI. It is notable that both the RUCAM and the M&V
scales are heavily weighted based upon whether rechallenge
with an offending medication results in repeat DILI.
Rechallenge with varenicline was not attempted in our
patient due to concerns for his safety.To date, there has been one previously published case
of DILI associated with varenicline. In 2009, Franck and
Sliter described the case of a 53 year old man with HCV
and alcohol-induced cirrhosis who developed a predom-
inant hepatitis after being initiated on varenicline for
smoking cessation while awaiting liver transplantation.
The patient developed a significant hepatitis within
4 weeks of beginning varenicline therapy that resolved
after discontinuing the medication. In contrast to our
patient, the previously published case involved a patient
with cirrhosis and did not demonstrate a substantial rise
in the bilirubin level. Data on the INR were not
reported.
Pharmacoepidemiological studies have suggested that
certain pre-existing disease states and certain physio-
chemical properties of certain classes of drugs might in-
crease the risk of idiosyncratic DILI, although the data
regarding this issue are equivocal [15]. Interestingly, the
published pharmacokinetics of varenicline demonstrate
that it is not substantially metabolized by the liver and is
eliminated via glomerular filtration. Therefore, there are
currently no recommended dose adjustments or precau-
tions for varenicline in patients with liver disease.
While the presence of underlying liver disease and
HCV in the present case and that reported previously by
Franck and Sliter may be coincidental, it is also of po-
tential clinical relevance. Both chronic liver disease and
smoking are prevalent in the U.S. adult population. Cur-
rently, 19.6 % of the U.S. adult population smokes [16].
And among individuals with HCV this rate is even
higher, estimated at 58 % [17]. As Franck and Sliter note
in their case report, it is commonly recommended by
liver transplant programs that patients being considered
for liver transplantation be encouraged to abstain from
smoking. Because sustained-release bupropion is recom-
mended for use with extreme caution in cirrhotic
patients, varenicline represents the only other non-
nicotine replacement pharmacologic intervention for
smoking cessation in this population. Therefore patients
may be at risk for DILI if an under-explored association
between hepatocellular dysfunction and varenicline in
the setting of HCV, or any chronic liver disease, exists.
The case presented here has been reported to Med-
Watch. Future cases of suspected varenicline-induced
hepatotoxicity should be reported and efforts to delin-
eate the mechanism of injury undertaken.Consent
Written informed consent was obtained from the patient
for publication of this case report. A copy of the written
consent is available for review by the Editor-in-Chief of
this journal.
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